CAM
CCCC icon

Congress Asset Management’s C4 Therapeutics CCCC Stock Holding History

Congress Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.18M Buy
1,256,692
+253,255
+25% +$944K 0.03% 271
2026
Q2 		$4.69M Buy
1,003,437
+172,813
+21% +$591K 0.03% 252
2026
Q1 		$2.18M Buy
+830,624
New +$1.96M 0.02% 298

Other funds holding CCCC

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Congress Asset Management's CCCC Position: Q3 2026 in Review

Congress Asset Management increased its C4 Therapeutics (CCCC) stake by 25% in Q3 2026, buying an estimated $944K and bringing the position to 1,256,692 shares worth $4.18M. The position accounts for 0.03% of the portfolio, ranked #271.

Congress Asset Management first reported a position in CCCC in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.69M in Q2 2026. 2 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • Congress Asset Management held 1,256,692 shares of C4 Therapeutics worth $4.18M as of Q3 2026.
  • Congress Asset Management bought 253,255 C4 Therapeutics shares in Q3 2026, an estimated $944K.
  • C4 Therapeutics made up 0.03% of Congress Asset Management's portfolio in Q3 2026, its #271 holding.
  • Congress Asset Management first reported a position in C4 Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Congress Asset Management's C4 Therapeutics position peaked at $4.69M in Q2 2026.
  • 2 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Congress Asset Management's 13F filing for Q3 2026, filed 6 Oct 2026.